Internal Medicine, Hematology & Oncology · Massillon, OH
NPI
1043274525
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
7337 Caritas Cir NW, Suite 150
Massillon, OH, 44646
Phone (330) 479-3042
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.0M
189,781 services
Medicare patients, 2024
710
Average age 74
Drug cost, 2024
$9.2M
1,953 prescriptions
Company payments, 2025
$4,087
From 58 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Scott W McGee was code J1439 (injection, ferric carboxymaltose, 1 mg), 70,500 times for 60 patients. In total Scott W McGee billed 189,781 services in 139 codes, and Medicare paid $2.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-12-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 70,500 | 60 | $0.86 | $60K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 12,300 | 30 | $4.39 | $54K |
| J0897 Injection, denosumab, 1 mg | Office | 9,180 | 64 | $20.31 | $186K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 8,000 | 11 | $44.69 | $358K |
| J9267 Injection, paclitaxel, 1 mg | Office | 7,655 | 15 | $0.08 | $604 |
| J0185 Injection, aprepitant, 1 mg | Office | 5,460 | 15 | $1.34 | $7,342 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 4,215 | 18 | $6.27 | $26K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 3,169 | 11 | $20.68 | $66K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,831 | 44 | $0.09 | $162 |
| 85025 Blood Count | Office | 1,809 | 517 | $7.51 | $14K |
| 36415 Venipuncture Blood Collection | Office | 1,689 | 512 | $8.58 | $14K |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 707 | 11 | $3.47 | $2,456 |
| 99214 Office E&M - Established | Office | 568 | 235 | $96.36 | $55K |
| 96372 Injection Administration | Office | 540 | 152 | $10.84 | $5,852 |
| J9190 Injection, fluorouracil, 500 mg | Office | 480 | 11 | $2.27 | $1,089 |
By year: 2022 $1.7M for 150,587 services; 2023 $2.2M for 206,232 services; 2024 $2.0M for 189,781 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,809 | 517 | $7.51 | $14K |
| 36415 Venipuncture Blood Collection | 1,689 | 512 | $8.58 | $14K |
| 80053 Clinical Chemistry | 448 | 246 | $10.29 | $4,608 |
| 82728 Clinical Chemistry | 210 | 123 | $12.99 | $2,727 |
| 83540 Clinical Chemistry | 207 | 123 | $6.16 | $1,275 |
| 83550 Clinical Chemistry | 206 | 123 | $8.33 | $1,715 |
| 83615 Clinical Chemistry | 137 | 72 | $5.92 | $811 |
| 82607 Clinical Chemistry | 49 | 40 | $14.78 | $724 |
| 83735 Clinical Chemistry | 32 | 15 | $6.57 | $210 |
| 82306 Clinical Chemistry | 27 | 25 | $27.94 | $754 |
Medicare prescription drug claims, 2024
In 2024, the drug Scott W McGee prescribed most often to Medicare patients was Anastrozole, with 211 prescriptions and refills. In total Scott W McGee wrote 1,953 Medicare prescriptions that cost $9.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 211 | 411 | 59 | $3,569 |
| Eliquis Apixaban | 118 | 143 | 24 | $85K |
| Xtandi Enzalutamide | 76 | 76 | Under 11 | $1.1M |
| Revlimid Lenalidomide | 73 | 73 | 11 | $1.3M |
| Doptelet Avatrombopag Maleate | 61 | 61 | 13 | $1.1M |
| Procrit Epoetin Alfa | 57 | 57 | Under 11 | $163K |
| Valacyclovir Valacyclovir Hcl | 56 | 79 | 13 | $2,628 |
| Hydroxyurea Generic | 56 | 110 | 15 | $908 |
| Prednisone Generic | 52 | 57 | 24 | $209 |
| Dexamethasone Generic | 51 | 63 | 18 | $879 |
| Ondansetron Hcl Generic | 49 | 49 | 28 | $5,725 |
| Anagrelide Hcl Generic | 46 | 66 | Under 11 | $4,978 |
| Acyclovir Generic | 46 | 58 | 14 | $568 |
| Bortezomib Generic | 44 | 44 | Under 11 | $81K |
| Imbruvica Ibrutinib | 36 | 36 | Under 11 | $563K |
Brand drugs: 809 claims; generic drugs: 1,144 claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Scott W McGee $4,087 ($4,087 in general payments such as food, travel and fees) from 58 companies. The largest payer was Merck Sharp & Dohme LLC with $404.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 14 | $404 |
| Abbvie Inc. ABBV | 15 | $289 |
| Astellas Pharma US Inc 4503.T | 8 | $246 |
| Pfizer Inc. PFE | 12 | $204 |
| Daiichi Sankyo Inc. 4568.T | 11 | $193 |
| Janssen Biotech, Inc. JNJ | 9 | $168 |
| Novartis Pharmaceuticals Corporation NVS | 8 | $161 |
| Caris MPI, Inc. | 7 | $153 |
| Incyte Corporation INCY | 7 | $149 |
| Genentech USA, Inc. ROG.SW | 8 | $147 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.